Clinical Trial

The Lymphocytic Infiltrate of Lung Tumors.

Study acronym: TREGILC
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 29, 2024 (before its estimated January 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
The study is configured as a monocentric observational transversal biological study. The main objective of the study is the reconstruction of the molecular organization of tumors of the thoracic cavity, in particular non-small cell lung cancer (NSCLC). The study involves the collection of clinical data and biological material (blood and tumor tissue) from 70 subjects diagnosed with thoracic tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-17.
Trial Details
NCT Number NCT06470607
Lead Sponsor Scientific Institute San Raffaele
Conditions Lung Cancer, Immune System
Enrollment 70 participants
Start Date 2023-01-20
Primary Completion 2026-01-20 (estimated)
Study Completion 2028-01-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-29